Navigation Links
Quanticel Pharmaceuticals Enters Into Strategic Cancer Drug Discovery Collaboration With Celgene Corporation
Date:11/4/2011

SAN FRANCISCO and SUMMIT, N.J., Nov. 4, 2011 /PRNewswire/ -- Privately held biotechnology company Quanticel Pharmaceuticals Inc. and Celgene Corporation (NASDAQ: CELG), together with Versant Ventures, today announced they have entered into an exclusive, strategic collaboration to discover and develop first-in-class cancer drugs.  

Under the terms of the agreement, Celgene will commit $45M to Quanticel during the initial three-and-a-half-year alliance term with the ability to extend the collaboration in exchange for additional funding.  Celgene will also take an equity stake in Quanticel and will retain an exclusive option to acquire the company.

During the collaboration, Quanticel will utilize its platform to conduct single-cell genomic analysis of patient tumor samples and to identify predictive biomarkers for Celgene investigational drugs.  Quanticel will also leverage its platform to perform independent drug discovery to generate its own drug candidates, and Celgene will have the ability to access this pipeline through its acquisition option.

"We all share a sense of urgency to create truly meaningful cancer medicines, and understand that new strategies that address all tumor cell populations are required for effective therapy," said Stephen Kaldor, Ph.D., Chief Executive Officer at Quanticel.  "Celgene's global research and development capabilities plus the long-term financial commitment to Quanticel enable us to rapidly build the research and development applications of our platform, and to accelerate the potential growth of our pipeline."

"Quanticel's platform approach provides a unique advantage for defining mechanisms of sensitivity and resistance, and for validating and pursuing novel targets for difficult-to-treat cancers," said Thomas Daniel, M.D., President, Global Research and Early Development at Celgene.  "We view t
'/>"/>

SOURCE Quanticel Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015  ResMed Inc. (NYSE: RMD ) ... 2015.  Revenue for the quarter was $453.1 million, a ... 30, 2014 (a 17 percent increase on a constant ... the quarter ended June 30, 2014.  Diluted earnings per ... quarter ended June 30, 2014.  The ...
(Date:7/30/2015)... July 30, 2015  EP Global Communications, Inc. (Public ... recently contacted the Company about discussing EPGL,s electronic ... as Monday, August 3, 2015.  Novartis CEO ... that the coming electronic contact lens market could ... the next several years.  Novartis partnered with Google ...
(Date:7/30/2015)... July 30, 2015  Unichem Pharmaceuticals ( USA ... of Hydrochlorothiazide tablets 25 mg 1000-count bottle to the ... precautionary measure due to the identification of a Clopidogrel ... The risk associated with mistakenly taking a ... increased probability of experiencing Clopidogrel,s side effects which include ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
... Ellman International, Inc., a New York based developer, manufacturer ... procedures, announced that Frank D. D,Amelio will join its ... (COO), Executive Vice President. "We are proud to welcome ... help guide the company,s continued growth," said Chief Executive ...
... This month, Minnesotans are recognized for their outstanding ... and for their donations of the blood component, plasma, ... Throughout September, Minnesota Gov. Tim Pawlenty is recognizing "Plasma ... to raise awareness for the rare, genetic diseases treated ...
Cached Medicine Technology:Ellman International Announces Executive Team Hire 2Minnesotans Help Produce As Well As Benefit from Lifesaving Therapies 2
(Date:7/31/2015)... ... July 31, 2015 , ... In the most recent ... Court in the Northern District of Illinois, Androgel testosterone attorneys report that a “Mini ... docket entry was made recording the minutes of the status conference, which was held ...
(Date:7/31/2015)... ... July 31, 2015 , ... People love to feel like ... where price is an important factor to clients when choosing to purchase a ... the Preferred Producer Multi-Life Discount program, where advisers pass savings onto their clients. ...
(Date:7/30/2015)... ... July 31, 2015 , ... Reduce Human Error on ... by FDAnews and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 – Raleigh, NC, ... drug, biologic and device firms reduce manufacturing errors by 50 percent or more, ...
(Date:7/30/2015)... ... 2015 , ... As more hospitals across the country see the value in ... challenge. Because of growing competition, it is more important than ever to market ... The team at Wound Care Advantage has found that while many hospitals ...
(Date:7/30/2015)... Miami, FL (PRWEB) , ... July 30, 2015 ... ... a new online program entitled " Lovetraction Lines ." It's for women interested ... in the men they desire. The course, which officially launched to the public ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:Secura Consultants Gives Advisers Competitive New Edge with Multi-Life Discount Program 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2
... real-time imaging and image guidance systems for use in,the operating room, will be holding its annual ... DATE: May ... 9:30 am, Eastern Daylight Time, LOCATION: ... 150 King Street West ...
... Using ... ImmunoCAP -, PORTAGE, Mich., May ... and Clinical Immunology revealed variations in,the results of three common allergy diagnostic ... specialists at,Mount Sinai School of Medicine, determined that the laboratory results from,two ...
... May 8 In March, AHIP,s Board of,Directors ... the,Medicare Advantage and Medicare Part D plan marketing ... issued its new regulations., (Logo: http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ... to ensure beneficiaries can rely on the,information being ...
... prolongs the life of these growth-driving molecules in breast ... Emory University,s Winship Cancer Institute. , The results are ... journal Molecular Cell. , Most breast cancers contain estrogen ... of the hormone estrogen. Their presence can determine whether ...
... May 8, 2008 People with diagnosed diabetes are nearly ... by arthritis hinders the successful management of both diseases, according ... released today by the Centers for Disease Control and Prevention ... kind to look at the relationship between arthritis and diabetes ...
... Neuroscientists at Johns Hopkins have discovered that mice ... exhibit a number of schizophrenia-like behaviors. The finding ... in the development of schizophrenia and related psychiatric ... for developing therapies. , The BACE1 enzyme, ...
Cached Medicine News:Health News:Novadaq Technologies Notice of Annual Meeting 2Health News:Novadaq Technologies Notice of Annual Meeting 3Health News:Data Show Common Allergy Tests Are Not Interchangeable 2Health News:Data Show Common Allergy Tests Are Not Interchangeable 3Health News:Previously unseen switch regulates breast cancer response to estrogen 2Health News:New report: Arthritis is a potential barrier to physical activity for adults with diabetes 2Health News:Hopkins researchers discover new link to schizophrenia 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: